Premature ovarian failure and infertility are adverse effects of cancer therapies. The mechanism underlying chemotherapy-mediated depletion of the ovarian reserve remains unclear. Here, we aim to identify the signaling pathways involved in the loss of the ovarian reserve to prevent the damaging effects of chemotherapy. We evaluated the effects of cyclophosphamide, one of the most damaging chemotherapeutic drugs, against follicle reserve. In vivo studies showed that the cyclophosphamide-induced loss of ovarian reserve occurred through a sequential mechanism. Cyclophosphamide exposure induced the activation of both DNAPK-gH2AX-checkpoint kinase 2 (CHK2)-p53/TAp63a isoform and protein kinase B (AKT)forkhead box O3 (FOXO3) signaling axes in the nucleus of oocytes. Concomitant administration of an allosteric ABL inhibitor and cyclophosphamide modulated both pathways while protecting the ovarian reserve from chemotherapy assaults. As a consequence, the fertility of the treated mice was prolonged. On the contrary, the administration of an allosteric ABL activator enhanced the lethal effects of cyclophosphamide while shortening mouse fertility. Therefore, kinase-independent inhibition may serve as an effective ovarian-protective strategy in women under chemotherapy.
Introduction
Premature ovarian failure and infertility are frequent consequences of cancer therapy 1 .
Chemotherapy triggers the degeneration of the ovarian reserve 2, 3 , a source of fertilizable eggs during the entire reproductive life of a female. Preserving the ovarian reserve during cancer treatment is a major concern for the maintenance of fertility and to ameliorate the quality of life of survivors. Studies in transgenic mouse models have revealed the role of several molecules in the maintenance of ovarian reserve following ionization radiation (IR) treatment. The alpha TAp63 isoform (TAp63a) was thought to be a key mediator of IRinduced ovarian reserve loss 4 . Lack of TAp63a expression in mouse oocytes promoted resistance to the lethal effects of IR 5 . IR-induced TAp63 activation depended on a conformational transition of the molecule 6 . The pro-apoptotic proteins PUMA and Noxa may act as downstream effectors of TAp63a 7 . In mice, checkpoint kinase 2 (CHK2) is essential for DNA damage surveillance in female meiosis 8 . Moreover, the lack of CHK2 expression affects TAp63 activation following IR treatment 8 . In vitro experiments in ovarian culture system showed that the transient administration of a CHK2 inhibitor II hydrate may preserve oocyte viability following IR treatment 9 . Another study demonstrated that CHK2 inhibitor II hydrate affected the activities of a broad spectrum of kinases and impacted the global repression of the DNA damage response (DDR) in cultured ovaries 10 , thereby raising some questions about its specificity. Tuppi et al reported that CHK2 and the executioner kinase CK1 are both involved in the TAp63a-mediated oocyte degeneration in cultured ovaries exposed to chemotherapy 11 . As cultured mouse ovaries exposed to chemotherapeutic drugs may not recapitulate the signaling pathways physiologically occurring in the ovary in vivo, we aimed to perform all our experiments under in vivo conditions. We evaluated the effects of cyclophosphamide, a chemotherapeutic agent commonly used for the treatment of pediatric cancer patients. Cyclophosphamide is transformed in the liver into active alkylating metabolites, which induce the formation of DNA adducts. How cyclophosphamide contributes to ovarian follicle depletion is yet incompletely understood and is debatable 12 .
Meirow et al suggest that the mechanism underlying cyclophosphamide-induced oocyte loss comprised the accelerated activation of primordial follicle that results in a "burnout" effect 13 .
However, chemotherapeutic drugs may directly damage the primordial follicle and induce apoptosis. The extent of ovarian reserve loss also depends on the type and dosage of the chemotherapeutic agent 14 . Understanding the molecular basis underlying the effect of chemotherapy on quiescent primordial follicles is therefore essential for the identification of an effective co-treatment that may simultaneously preserve fertility in women 15, 16 . Here, we investigated the in vivo consequences of different doses of cyclophosphamide on the ovarian reserve. We used a pre-pubertal mouse model to evaluate the effect of transient administration of small molecule kinase inhibitors to identify putative ferto-protective adjuvants 17 to limit the damaging effects of chemotherapy.
Results

Cyclophosphamide triggers a dose-dependent loss of primordial follicles.
We investigated the effects of cyclophosphamide on perinatal mouse ovaries. We injected mice (at postnatal day 7, P7) with different doses of cyclophosphamide (ranging from 50 to 200 mg/kg). One day after injection, ovaries were dissected and analyzed with TdTmediated dUTP nick-end labelling (TUNEL), immunofluorescence (IF), and immunohistochemistry (IHC) assays. Cyclophosphamide administration induced a dosedependent increase in the number of TUNEL-positive granulosa cells surrounding the growing follicles ( Fig. 1A ). Cell death in the ovarian follicle reserve was observed with IF staining for cleaved poly ADP ribose polymerase (PARP) ( Fig. 1B) . We found apoptotic oocytes in the groups treated with low doses of cyclophosphamide (50-75 mg/kg), while higher doses of cyclophosphamide (100-200 mg/kg) activated cleaved PARP in the granulosa cells of large growing follicles (see dashed yellow box in Fig. 1B ). We also detected the phosphorylation of the histone variant H2AX at Ser139 residue, also named as gH2AX, an early hallmark of DDR, in the nucleus of cyclophosphamide-damaged oocytes (Fig. 1C ). Temporary hair loss was reported a week later in cyclophosphamide-injected animals ( Fig. 1D ).
DNA-PK is activated in the nucleus of reserve oocytes following cyclophosphamide treatment.
To investigate the mechanism underlying cyclophosphamide-induced follicle death, we evaluated the activation of the apical DDR kinase (DNA-PK) with phospho-specific antibodies after 16 h of cyclophosphamide injection. The presence of apoptosis in the primordial/primary follicle population was consistent with the activation of DNA-PK in the nucleus of reserve oocytes ( Fig. 2 ). Phosphorylation of the histone variant H2AX at Ser139 was observed in the nucleus of damaged oocytes. The majority of oocytes were positive for both DNA-PK and gH2AX expression at every dose of cyclophosphamide ( Fig. 2 ). Confocal images of middle ovarian sections obtained from cyclophosphamide-injected mice showed that the oocytes with a strong signal for gH2AX or p-DNA-PK had lower expression of TAp63 We observed activation of checkpoint kinase CHK2 and p53 in the nucleus of the damaged oocytes ( Supplementary Fig. 1 ). Both CHK2 and p53 are involved in the removal of oocytes with unrepaired meiotic DNA double-strand breaks (DBSs) 8 . Thus, the cyclophosphamideinduced loss of ovarian reserve involves the activation of the DNA-PK-gH2AX-CHK2-p53/TAp63a signaling axes.
We investigated the mechanisms underlying the cyclophosphamide-induced follicle death following the activation of the protein kinase B (AKT) pathway using phospho-specific antibodies after 16 h treatment with cyclophosphamide ( Supplementary Fig. 2 ). The AKT pathway is involved in primordial follicle activation through the regulation of the activity of the forkhead box O3 (FOXO3) transcription factor 18 . Upon phosphorylation, AKT may enter the nucleus and phosphorylate FOXO3, which eventually leaves the nucleus and enables follicular activation.
Following cyclophosphamide injection, p-AKT and p-FOXO3 were detected in the nucleus of reserve oocytes. We also observed expression of p-AKT and gH2AX in the reserve oocytes ( Supplementary Fig. 2 ). Thus, the presence of the early marker of DDR was consistent with the activation of the AKT-FOXO3 pathway.
GNF-2 prevents gH2AX phosphorylation in the nucleus of reserve oocytes.
Previous studies have revealed the protective role of an ABL kinase inhibitor (imatinib) on ovarian reserve in cisplatin-induced degeneration 19, 20, 21, 22 . However, the mechanism underlying oocyte protection by imatinib remains unclear. As discussed in a recent paper 10 , cisplatin induced a response that activated the pathways different from those activated by IR. Cisplatin toxicity gradually accumulated from multiple sources (lipids, proteins, etc.) and induced integrated pathways of the two p53 homologs (TAp63a and TAp73a) 10 in follicles.
Here, we tested whether the allosteric ABL compounds affect the DDR induced by cyclophosphamide. In our experiments, we used an allosteric activator of ABL kinase 23 ( Supplementary Fig. 3 ) to validate the effect of ABL compounds in vivo. We treated female mice with cyclophosphamide in the presence of GNF-2. Concomitant administration of GNF-2 resulted in a significant reduction in the number of TUNEL-positive granulosa cells in a dose-dependent manner ( Fig. 3 ). We failed to observe any apoptosis in reserve oocytes ( Fig. 3 ). Co-treatment of cyclophosphamide and GNF-2 also affected DNA-PK activation and the consequent gH2AX phosphorylation in the nucleus of reserve oocytes ( Fig. 3 ).
On the contrary, the concomitant administration of DPH (an allosteric ABL activator) enhanced DDR activation ( Fig. 4 ) and oocyte apoptosis induced by cyclophosphamide.
IF assay results revealed the increase in the number of gH2AX-positive oocytes after cyclophosphamide treatment. Therefore, we investigated whether ATM phosphorylates H2AX in the damaged oocytes. IF assay results showed that ATM phosphorylation was coupled with a decrease in TAp63 expression in the nucleus of reserve oocytes, as reported for p-DNA-PK ( Supplementary Fig. 4 ). The concomitant administration of GNF-2 also prevented ATM activation in the nucleus of reserve oocytes.
In conclusion, GNF-2 and cyclophosphamide co-treatment restricted apoptosis in ovarian reserve through the prevention of the activation of the DNA-PK(ATM)-gH2AX-CHK2-p53/TAp3 signaling axes. We also evaluated the effect of allosteric compounds on the activation of AKT-FOXO3 pathway. Co-treatment of cyclophosphamide with GNF-2 prevented the translocation of p-AKT in the nucleus of the oocyte, while DPH enhanced the activation of AKT and concomitant phosphorylation of FOXO3 ( Supplementary Fig. 5 ) in the ovarian reserve assaulted by cyclophosphamide.
GNF-2 prevents the cyclophosphamide-induced loss of follicle reserve.
We dissected and analyzed the cyclophosphamide-treated ovaries by western blotting.
Ovarian lysates from mice injected with PBS or cyclophosphamide (100 mg/kg) alone or in combination with kinase inhibitors targeting ABL (GNF-2, imatinib), DNA-PK (NU7441), or ATM (KU55933) revealed the GNF-2-mediated prevention of TAp63 activation (i.e., absence of mobility shift) and gH2AX generation. NU7441 and KU55933 did not prevent TAp63 activation or gH2AX generation ( Fig. 5A ). On the other hand, imatinib partially prevented TAp63 activation/shift and gH2AX expression. These results were also confirmed by IHC assay performed on the ovaries dissected 3 days after injection ( Fig. 5B ). Ovarian sections showed a massive depletion in primordial and primary follicles after cyclophosphamide treatment, whereas a significant rescue in follicle reserve was observed in the ovaries cotreated with cyclophosphamide and GNF-2 ( Fig. 5C ). We counted primordial, primary, and secondary follicles from middle-ovary sections (Fig. 5D ), as previously described 22 . We failed to observe any significant difference in secondary follicles in cyclophosphamidetreated and control groups.
Imatinib and NU7441 partially mitigate the toxic effect of cyclophosphamide.
We evaluated the effect of different doses of two kinase inhibitors imatinib and NU7441.
Both compounds bind to the ATP-binding cleft of kinases and are quite selective for their main target kinases. However, imatinib binds to other kinases such as platelet-derived growth factor receptor (PDGFR) and c-KIT 24 , while NU7441 also inhibits phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3K) and has little activity against ATM and ATR 25 . We assessed the effect of these compounds in combination with cyclophosphamide. We injected mice with cyclophosphamide (100 mg/kg) in the presence of each inhibitor. TUNEL assay result showed that the co-treatment with imatinib or NU7441 had milder effects on the prevention of granulosa cell death than co-treatment with GNF-2 ( Fig. 6A and Supplementary Fig. 6A ). We found that imatinib and NU7441 failed to prevent DNA-PK-gH2AX-TAp63 activation ( Fig. 6B and Supplementary Fig. 6B ). However, at low dose, imatinib temporarily prevented apoptosis in follicle reserve (Fig. 6C ). This observation was also confirmed by IHC assay (Fig. 5B ) performed in ovarian sections dissected after 3 days of injection (Fig. 6D ). NU7441 and cyclophosphamide co-treatment mildly mitigated apoptosis in follicle reserve ( Supplementary Fig. 6C ) as confirmed by IHC staining (Fig. 5B) of the ovarian sections dissected 3 days after injection ( Supplementary Fig. 6D ). In conclusion, imatinib and NU7441 are less effective than the allosteric inhibitor GNF-2 in the prevention of cyclophosphamide-induced follicle loss. This observation may depend on the inhibition of kinases, including the receptor tyrosine kinase c-KIT and PIK3 that play important roles in follicle reserve. On the contrary, no known target for the allosteric compound GNF-2, other than ABL kinases, has been reported so far 26 .
GNF-2 prolongs fertility in female mice injected with cyclophosphamide.
To investigate the long-term effect of concomitant GNF-2 administration, co-treated mice were allowed to grow and eventually mated with fertile males. Mice were injected at P7, 3 days after few ovaries from each experimental group were analyzed with IHC assay ( Fig.   7A and Supplementary Fig. 7A ). We also monitored hair recovery for each experimental group after 2 weeks of injection ( Supplementary Fig. 7B ) and evaluated pubertal ovaries of cyclophosphamide-treated mice by IHC staining before fertility test ( Supplementary Fig. 8 ).
In addition, we measured the average weight of mice from each experimental group over 4 weeks from injection (Fig. 7B) . We followed the mating capability and the number of pups delivered during six breeding rounds. No evident differences in behavior and development were observed between the off-springs from each experimental group during the first postnatal week. However, we observed that fertility was impaired in the females injected with cyclophosphamide and DPH ( Fig. 7C and D) . The mice treated with cyclophosphamide and DPH were infertile after three mating rounds, quite before those treated with cyclophosphamide. On the other hand, co-treatment of mice with GNF-2 and cyclophosphamide prolonged the fertility as compared to cyclophosphamide-treated mice and increased the cumulative number of pups compared to cyclophosphamide + DPH and cyclophosphamide groups (Fig. 7E) . The gross morphology of the ovaries dissected from adult mice showed a clear difference in size between gonads of each experimental group.
The analysis of ovarian sections by IHC assay with Msy2 confirmed the nearly complete absence of follicle reserve in the ovaries from cyclophosphamide + DPH and cyclophosphamide groups (Fig. 7F ).
Discussion
Cyclophosphamide is currently used for the treatment of pediatric cancers. A major concern is the ovarian reserve depletion induced by cyclophosphamide treatment. In the present study, we used a pre-pubertal mouse model to show in vivo the signaling axes induced by cyclophosphamide. We also tested small molecules that could limit the cyclophosphamideinduced toxicity by acting as putative 'ferto-adjuvants."
Genetically modified mouse models have facilitated the study of the signaling pathways induced in ovary by IR or chemotherapy. Gene targeting approaches may oversimplify the interpretation of the results. The lack of a single node/protein could affect signaling circuits at different levels and the observations reported herein in knockout mice may be attributed to the multiple effects that are difficult to dissect. Small molecules offer unique advantages in terms of interpretation of results because of their transient inhibitory effects on targeted proteins (and/or pathways). Pharmaceutical inhibitors may have a direct relevance with patient care.
Our study showed that cyclophosphamide induced apoptosis in the ovarian reserve through signaling axes involving DNA-PK/(ATM), CHK2, p53, and TAp63a. In addition, the cotreatment of cyclophosphamide and GNF-2 affected the DDR induced by cyclophosphamide in the ovary. We also showed that the reserve oocytes rescued from immediate degeneration were healthy enough to produce normal off-springs. Gross morphology and IHC analyses of ovary sections performed either before fertility test or after infertility detection in the first group of treated mice confirmed that the concomitant administration of GNF-2 and cyclophosphamide had long-term effects. Our data are reinforced through the use of an allosteric activator (DPH) that exerted opposite effects as compared to GNF-2.
Co-treatment with DPH and cyclophosphamide enhanced the DDR induced by cyclophosphamide in ovaries and shortened mouse fertility. We also compared the effect of the transient administration of inhibitors targeting DDR apical kinases and observed mild protective effects exclusively at low doses of kinase inhibitors. Why allosteric compounds targeting ABL are more effective than ATP-competitive kinase inhibitors in rewiring apoptotic pathways induce by cyclophosphamide is questionable. We hypothesized that either i) the theory of "burnout effect" 13 or ii) the direct DNA damage of follicle reserve in the ovary assaulted by cyclophosphamide may be associated with this effect. Both theories rely on the fact that the damaged somatic cells communicate with the oocyte. In this scenario, allosteric ABL compounds could affect follicle apoptosis by targeting the transmission of stress signals from pre-granulosa cells to the oocyte. Although the molecular details remain unclear, our current model suggests that ABL kinases may act as "allosteric devices" that contribute to fuel the molecular events underlying stress signaling/DDR in the follicles 27 . This model is supported by the observation that GNF-2 prevents the activation of the AKT-FOXO3 signaling axis induced by cyclophosphamide. We also found that DPH promotes the activation of the AKT-FOXO3 signaling axis following cyclophosphamide treatment and that the reserve oocytes were positive for both p-AKT/p-FOXO3 and gH2AX expression.
Thus, the presence of the early marker of DDR is consistent with the activation of the AKT-FOXO3 pathway. These observations suggest that oocytes leave their follicular quiescence to initiate the DNA damage signaling pathways that end in oocyte apoptosis. Whether this is a general mechanism occurring with other DNA-damaging chemotherapeutic drugs and IR is yet unknown.
Evidences suggest that ABL kinase inhibitors protect the ovarian reserve from cisplatininduced degeneration 19, 20, 21, 22 . However, the mechanism underlying the imatinib-mediated protection of oocytes remains debated. Genetic studies have shown that the oocyte ABL kinases are dispensable for cisplatin-induced TAp63a activation 10 . However, ABL kinases in complex with inhibitors may not recapitulate the results observed in ABL null mice, given that ABL proteins take part to opposing signaling pathways in cells 28 .
Recent studies have identified CHK2 and p53 as two important players in the efficient removal of oocytes with unrepaired meiotic DNA DBSs 8 . In addition, CHK2-dependent TAp63a phosphorylation is a key event induced in response to IR 6, 8 . We show that cyclophosphamide induced DNA damage checkpoint pathways that involve signaling of DNA-PK to CHK2, which in turn communicates with p53 and TAp63, revising a previously proposed model 8 . We found p-p53 (Ser15) in the nucleus of the damaged oocytes, supporting the direct role of p53 in driving the apoptotic response of follicles. This observation is intriguing, as TAp63a is considered as a key player in quality control of germ cells. However, activated TAp63a exerts modest activity as a transcription factor as compared with p53; thus, the quality control and apoptotic response induced by cyclophosphamide require the concomitant outcomes of both factors.
A recent work showed that mouse models lacking PUMA (a pro-apoptotic protein) retained fertility after chemotherapy 29 . This observation supports the results that reserve oocytes from PUMA −/− mice may sufficiently repair themselves to support healthy off-springs. These findings strengthen the argument that oocytes are in fact capable of efficient DNA repair in response to the inhibition of the apoptotic pathway in the ovary 30 .
The concomitant administration of GNF-2 and cyclophosphamide results in the inhibition of the AKT-FOXO3 signaling axis and DDR, thereby preventing cyclophosphamide-induced apoptosis of ovarian reserve. Thus, the feasibility of ferto-adjuvant therapies based on 
